Hold the Chemo | GenomeWeb

Hold the Chemo

TAILORx trial researchers say that most women with early stage breast cancer who receive a low recurrence risk score on Genomic Health's Oncotype DX test do well on hormonal therapy alone and are disease-free after five years, as GenomeWeb has reported.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.